Vascular Gene Transfer of the Human Inducible Nitric Oxide Synthase: Characterization of Activity and Effects on Myointimal Hyperplasia

Edith Tzeng,* Larry L. Shears II,* Paul D. Robbins,† Bruce R. Pitt,‡ David A. Geller,* Simon C. Watkins,§ Richard L. Simmons,*‡ and Timothy R. Billiar*
Departments of *Surgery, †Molecular Genetics and Biochemistry, ‡Pharmacology, and §Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, U.S.A.

ABSTRACT

Background: Nitric oxide (NO) has been shown to decrease myointimal hyperplasia in injured blood vessels. We hypothesize inducible NO synthase (iNOS) gene transfer even at low efficiency will provide adequate local NO production to achieve this goal.

Materials and Methods: A retroviral vector containing the human iNOS cDNA (DFGiNOS) was used to transfer the iNOS gene into vascular cells and isolated blood vessels to answer the following questions: can vascular endothelial and smooth muscle cells support iNOS activity and will low efficiency iNOS gene transfer suppress myointimal hyperplasia in injured porcine arteries?

Results: DFGiNOS-infected sheep pulmonary artery endothelial cells (SPAEC) expressed significant iNOS mRNA and protein, releasing nitrite levels of 155.0 ± 10.7 nmol/mg protein/24 h vs. 5.5 ± 1.1 by control cells. Transduced rat smooth muscle cells (RSMC) also expressed abundant iNOS mRNA and protein, but, in contrast to SPAEC, NO synthesis was dependent on exogenous tetrahydrobiopterin (BH₄) (291.8 ± 10.4 nmol nitrite/mg protein/24 hr with BH₄, 37.7 ± 2.6 without BH₄). Only porcine arteries infected with DFGiNOS following balloon injury exhibited a 3-fold increase in total NO synthesis and a 15-fold increase in cGMP levels over control vessels in a BH₄ dependent fashion, despite only a 1% gene transfer efficiency. Transfer of iNOS completely prevented the 53% increase in myointimal thickness induced by balloon catheter injury; the administration of a NOS inhibitor reversed this effect.

Conclusions: These in vitro findings suggest that vascular iNOS gene transfer may be feasible. Furthermore, a low gene transfer efficiency may be sufficient to inhibit myointimal hyperplasia following arterial balloon injury, although a source of BH₄ may be required.

INTRODUCTION

Arterial wall injury initiates a cascade of events, including platelet and inflammatory cell recruitment resulting in local mitogen release, that culminates in smooth muscle migration and proliferation (reviewed in Ref. 1). This sequence of events is thought to be important in the pathogenesis of intimal hyperplasia associated with restenosis as well as atherosclerosis. Such a predictable response to vascular injury may compromise the success of angioplasty and surgical bypass for obstructive vascular lesions. Many current experimental efforts focus on methods to minimize the local proliferative process and reduce neointima formation. Potentially efficacious agents under investigation include cytotoxic drugs, angiotensin-converting enzyme inhibitors (2), antisense oligonucleotides to block gene expression (3), and gene transfer to promote the local synthesis of antiproliferative agents (4,5). If one could inhibit the proliferative response of the injured tissue, the incidence of restenosis might be significantly reduced.

A vital component of normal vascular ho-
meostasis is endothelium-derived nitric oxide (NO). Vascular properties of nitric oxide (NO) include vasodilation (6,7), prevention of platelet adhesion and activation (8), inhibition of smooth muscle proliferation (9), and prevention of leukocyte-endothelial interactions (10). Under physiologic conditions, NO is derived from the endothelial constitutive NO synthase (ecNOS or Type III NOS), which synthesizes small quantities of NO in a calcium- and calmodulin-dependent fashion (11,12). Endothelial injury and dysfunction are common features of a number of disease processes, and the loss of NO synthetic capacity may contribute to the pathologic changes. For example, hypertensive states have been identified in which endothelium-derived NO is deficient, resulting in pathophysiologic alterations in the blood vessel (13,14). NO deficiencies may also exist at sites of injury incurred by angioplasty or surgical procedures (15,16). Others have reported evidence that increasing serum levels of the NOS substrate L-arginine (17,18) attenuates neointima formation at sites of vascular injury. Recent results in a rat carotid injury model indicates restoring ecNOS activity at the site of injury with liposome-mediated transfection prevents neointimal hyperplasia and preserves vasoreactivity (19).

Another approach to increase local NO levels is through the transfer of a different NOS isoform, the inducible NOS (iNOS or Type II NOS), to vascular target cells such as endothelial or smooth muscle cells. Distinct from the ecNOS, iNOS synthesizes much larger quantities of NO in a sustained manner and functions independent of intracellular calcium fluxes (reviewed in Ref. 20). Therefore, even if iNOS is expressed in relatively few cells, a wide field of cells could be exposed to NO independent of external agonists needed by the ecNOS to stimulate calcium fluxes. Because of technical limitations associated with vascular gene transfer strategies, a gene effective when expressed in low abundance could have distinct advantages. In these respects, iNOS could have important advantages over ecNOS as a therapeutic tool for the treatment of restenosis. A potential pitfall of NOS gene transfer rests in the ability of targeted cells and tissues to produce the cofactor tetrahydrobiopterin (BH₄) (21), essential for the function of all NOSs. To investigate the feasibility of human iNOS gene transfer, a retroviral vector expressing both human iNOS and the neomycin phosphotransferase (Neo) selectable marker was constructed. The iNOS retroviral vector was used to stably transfer high output iNOS activity to cultured endothelial cells and vascular smooth muscle cells as well as to arterial segments in vitro. We show that endothelial cells and smooth muscle cells can be engineered to express stably an active human iNOS enzyme with differential requirements for BH₄. Finally, low efficiency iNOS gene transfer to arterial segments was adequate to reduce significantly injury-induced myointimal hyperplasia.

**MATERIALS AND METHODS**

**Construction of Retroviral Vectors**

The human hepatocyte iNOS cDNA measuring 4145 bp in length was cloned in our laboratory as previously described (22) and was subcloned into the MFG retroviral vector (23) as follows: An Ncol site was created at the ATG start codon of the iNOS cDNA with polymerase chain reaction (PCR)-directed site-specific mutagenesis, altering base pairs 205 and 206 (no amino acid changes because the ATG starts at base pair 207). The 3' primer was complementary to the sequence at base pair 1252. The iNOS cDNA (140 ng) was subjected to PCR amplification in a thermal cycler (Perkin-Elmer Cetus; Norwalk, CT, U.S.A.). The 1-kb PCR product was digested with Ncol and EcoRI to generate a 854-bp 5' iNOS fragment. A 3' BamHI compatible site was created at base pair 3705 (the translational stop codon is located at base pair 3666) utilizing BclI linkers. The 2646 bp 3' to EcoRI to BclI fragment was then isolated. Ligation of the 5' and 3' iNOS fragments into the retroviral backbone, where an internal ribosome entry site (IRES) and a neomycin phosphotransferase (Neo) gene had been previously inserted at the 3' BamHI site, yielded the DFGiNOS construct (Fig. 1a). The IRES permits translation of a polycistronic mRNA. The control retroviral vectors MFGlacZ and BaglacZ were previously described (24,25) (Fig. 1 b and c). Both carry the β-galactosidase gene, while BaglacZ additionally carries the Neo gene.

**Production of Replication-Deficient Retrovirus**

The DFGiNOS plasmid was calcium phosphate transfected into the transient ecotropic packaging cell line BOSC23 (26). Viral supernatants were collected 72 hr after transfection and used to infect CRIP cells (27) to generate a stable amphotropic producer cell line. CRIP cells were
incubated with BOSC23 viral supernatant with 8 \( \mu g/ml \) polybrene (Sigma Chemical Co., St. Louis, MO, U.S.A.) and then selected with G418 (750 \( \mu g/ml \), Geneticin, Gibco-BRL, Grand Island, NY, U.S.A.). The BOSC23 supernatant had an estimated titer of 10^5 CFU/ml. Individual G418-resistant CRIP colonies were isolated and screened for nitrite (NO\(_2^-\)) production as an indirect measure of iNOS expression. The colonies generating the highest NO\(_2^-\) levels were tested for virus production by the number of G418-resistant NIH3T3 colonies following infection with serial dilutions of the CRIP-DFGiNOS supernatants. The BAG mobilization assay for replication competent helper virus was performed as previously described (28).

**Cell Culture**

BOSC23 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM), 10% fetal calf serum, 100 U/ml penicillin, 100 \( \mu g/ml \) streptomycin, and 4 mM glutamine and CRIP cells in DMEM, 10% calf serum, 50 U/ml penicillin, 50 \( \mu g/ml \) streptomycin, and 10 mM HEPES. Sheep pulmonary artery endothelial cells (SPAEC) were isolated by collagenase digestion and grown in OPTI-MEM I (Gibco-BRL), 10% sheep serum, 100 U/ml penicillin, 100 \( \mu g/ml \) streptomycin, 15 \( \mu g/ml \) endothelial cell growth supplement (Collaborative Biomedical Products, Bedford, MA, U.S.A.), and 10 U/ml heparin. At the second to third passage, cells were incubated with 1,1'-diodotyrosyl-1,3,3',3'-tetramethyl-indocarbocyanine perchlorate–labeled acetylated low density lipoprotein (DiIac-LDL; Biomedical Technologies Inc., Staughton, MA, U.S.A.) and cells preferentially incorporating DiIac-LDL were isolated by fluorescence activated cell sorting (FACstar; Becton Dickinson Immunocytometry, San Jose, CA, U.S.A.). Subcultures were routinely positive for DiIac-LDL uptake as well as von Willebrand factor (vWF). Rat pulmonary artery smooth muscle cells (RSMCs) were isolated from left pulmonary artery explants as previously described (29). The cells were maintained in DMEM/F12 (1:1 v/v) 10% fetal calf serum, 4 mM L-glutamine, 100 U/ml penicillin, and 100 \( \mu g/ml \) streptomycin. The cells had the characteristic spindle shape of smooth muscle cells and were positively identified by indirect immunofluorescence staining for \( \alpha \)-actin and smooth muscle-specific myosin. Only early passage RSMCs (passages 3–8) were utilized in the following experiments. All cell lines were grown at 37°C in a 5% CO\(_2\)/95% air incubator.

**Infection of Vascular Cells**

SPAECs and RSMCs at 50% confluence were infected for 8 hr with either DFGiNOS or BaglacZ viral supernatant with 8 \( \mu g/ml \) polybrene and selected in G418 (500–750 \( \mu g/ml \)). Following selection, >90% of BaglacZ-infected SPAECs and RSMCs possessed \( \beta \)-galactosidase activity by X-gal staining. All cells were cultured in 0.5 mM N^0^-monomethyl-L-arginine (l-NMA) to inhibit NO synthesis until 24 hr prior to experimentation. A subgroup of SPAEC-DFGiNOS was cultured without l-NMA for >14 days to study the effects of sustained high level NO production. l-NMA administration did not alter cell growth or morphology.

**RNA Isolation and Northern Blot Analysis**

Total cellular RNA was isolated from uninfected, BaglacZ, and DFGiNOS SPAECs and RSMCs as well as SPAEC treated for 6 hr with 1 mM N-
acetyl-penicillamine (NAP) or S-nitroso-N-acetyl-penicillamine (SNAP; Sigma) using RNAzol B as previously described (30). Aliquots (20 µg) of RNA were electrophoresed on a 0.9% agarose gel and blotted to GeneScreen (DuPont-NEN, Boston, MA, U.S.A.). After prehybridization, the membranes were hybridized to a DNA probe as described (31). A 2.3-kb human iNOS cDNA fragment served as the iNOS probe while a 4.1-kb human endothelial cNOS cDNA fragment served as the ecNOS probe. 18S rRNA served as a control for relative RNA loading.

**Cell Lysate Preparation**

Uninfected and BaglacZ- and DFGiNOS-infected SPAECs were washed and resuspended in protease inhibitor buffer (20 mM TES, pH 7.4, 2 mM DTT, 10% glycerol, 25 µg/ml Antipain, 25 µg/ml Aprotinin, 25 µg/ml Leupeptin, 25 µg/ml Chymostatin, 50 µM Phanenthroline, 10 µg/ml Pepstatin A) supplemented with 10 µM FMN, 10 µM FAD, and 5 µM BH₄. The cells were lysed by three freeze-thaw cycles, and the cytosolic fraction was isolated by centrifugation at 100,000 × g for 60 min at 4°C as previously described (32). Protein concentrations were measured with the BCA protein assay (Pierce, Rockford, IL, U.S.A.). For whole cell preparations, a similar procedure was performed without the centrifugation step.

**Western Blot**

Cell cytosols (100 µg) were electrophoresed through an 8% SDS-polyacrylamide gel and transferred to nitrocellulose membranes (Schleicher & Schuell, Keene, NH, U.S.A.) as described (33). Membranes were blocked with 5% milk/phosphate buffered saline/0.1% Tween-20 and hybridized with a monoclonal antiumouse macrophage iNOS antibody (1:2000 dilution; Transduction Laboratories, Lexington, KY, U.S.A.) that detects human iNOS, followed by a goat anti-mouse IgG linked to horseradish peroxidase (Schleicher & Schuell). Human hepatocyte cytosol isolated 14 h following stimulation with 5 U/ml human IL1β (Cistron, Pine Brook, NJ, U.S.A.), 500 U/ml human TNFα (Genzyme, Boston, MA, U.S.A.), 100 U/ml human IFNγ (Amgen, Thousand Oaks, CA, U.S.A.), and 10 µg/ml LPS (Escherichia coli 0111:B4; Sigma) served as a positive control. The membrane was developed with ECL reagents (DuPont-NEN) and exposed to Kodak X-Omat film for 1–20 min at room temperature. For ecNOS, 25 µg of whole cell preparations were electrophoresed. The primary antibody was monoclonal murine IgG against human ecNOS (1:2000 dilution; Transduction Laboratories) that detects ovine ecNOS.

**Assay for NO₂⁻ and NO₃⁻ Production**

Uninfected, BaglacZ, and DFGiNOS SPAECs and RSMCs were passaged to 6-well plates at near confluency in the presence of 0.5 mM L-NMA. Culture medium was then replaced with fresh medium and the cells were cultured for an additional 24 hr at which time the supernatants were assayed for accumulated NO₂⁻ using the Griess reaction (31). Measurements were also performed in the presence of L-NMA (0.5 mM) and/or BH₄ (100 µM). The cells in each well were then lysed with 1% Triton X-100/25 mM Tris phosphate/2 mM EDTA/10% glycerol and the protein concentration was quantified with the BCA protein assay. Some supernatants were also assessed for total NO₂⁻ and NO₃⁻ levels with a standardized HPLC assay utilizing an in-line column containing copper-coated cadmium as previously described (34).

**Arterial Organ Culture**

Femoral arteries were collected from anesthetized (sodium pentobarbital, 4 mg/kg) domestic pigs through bilateral groin incisions and immediately immersed into sterile phosphate buffered saline. The adventitia was gently dissected free, and some vessels were uniformly injured with a 4-French balloon catheter inflated to 10 atmospheres for 30 sec. All arteries were opened along the long axis, divided into 1-cm-long sections, and cultured in DMEM, 20% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, and 4 mM L-glutamine at 37°C as previously described (35). On culture Day 5, some arterial segments were incubated with 2 ml of either DFGiNOS or MF-GlacZ viral supernatant (both titers ~10⁶ CFU/ml) supplemented with polybrene (8 µg/ml) for 6 hr. Following infection, the vessels were transferred to fresh culture dishes to remove any explanted cells and were maintained in organ culture for a total of 14 days with daily media changes. After our initial observations that NO₂⁻ + NO₃⁻ release from the DFGiNOS-transfected vessels was BH₄ dependent, BH₄ (100 µM) was supplemented on a daily basis to all the cultures. L-NMA (0.5 mM) was added to some vessel preparations. On Day 14, culture supernatants were collected for NO₂⁻ + NO₃⁻ and cGMP determina-
tions. cGMP levels were measured with a commercial radioimmunoassay (NEN, Boston, MA, U.S.A.).

To evaluate efficiency of MFGlAcZ infection, vessel segments were fixed in 0.5% glutaraldehyde for 30 min and stained for β-galactosidase activity with X-gal. DFGiNOS segments were fixed in 2% paraformaldehyde for 1 hr at 4°C and cryoprotected in 30% sucrose overnight at 4°C. Vessels were then quick frozen with Histofreeze-2000 (Fisher, Pittsburgh, PA, U.S.A.) and 5-μm cryosections cut. Sections were mounted on glass slides, permeabilized with 2% paraformaldehyde/0.1% Triton X-100, blocked with 5% goat serum, and then incubated with the primary monoclonal antimurine iNOS antibody previously used for Western blot analysis. The antibody staining was visualized with immunoperoxidase. To measure myointimal thickness, semiserial sections were incubated for 60 min with rhodamine phalloidin (Molecular Probes, Inc., Eugene, OR, U.S.A.), which binds to actin. These preparations were visualized with indirect fluorescence microscopy (Nikon, FA) and recorded by a Sony DXC 930 camera linked to a computer. The myointimal thickness was quantified with the Optimas program (Optimas Corp., Seattle, WA, U.S.A.) at 25 random sites along the length of each vessel segment and calculated as the mean of all the measurements.

Some vessels were homogenized with a polytron and the RNA was extracted with RNAzol as described above. First strand cDNA synthesis was performed on 500 ng of total RNA in a volume of 10 μl with 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 1.0 mM dNTPs, 10 mM DL-dithiothreitol, 10 U human placental RNAase inhibitor, and 200 U MMLV reverse transcriptase (GIBCO, Gaithersburg, MD, U.S.A.) at 37°C for 60 min. cDNAs (100 ng) were combined in 50 μl in 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 200 μM dNTP, 1.5 mM MgCl2, 100 pM each PCR primer, and 1.25 U Taq DNA polymerase (Perkin-Elmer Cetus) and PCR amplification carried out with denaturation at 94°C for 1 min, annealing at 57°C for 2 min, and elongation at 72°C for 3 min for 40 cycles. The iNOS oligonucleotide primers specifically recognize the human hepatocyte iNOS cDNA sequence and do not detect rodent sequences. The 18-bp 5' primer spanned from base pair 3426 to 3444 of the iNOS cDNA with the sequence 5'-AGGACATCCTGCGGACGC-3' and the 3' primer spanned from base pair 3724 to 3741 with the sequence 5'-GCTTAAACCCCTCCTGTA-3'. The predicted PCR product is 316 bp. PCR amplification for Neo mRNA, unique to the DFGiNOS virus, was performed as another marker for expression of the iNOS transgene (Neo PCR product = 728 bp). Reverse transcriptase PCR for β-actin message served as a control. The β-actin PCR product measures 652 bp. PCR products were visualized on a 1.5% agarose gel.

**Statistical Analysis**

Values for NO2-, NO2- + NO3-, cGMP, and myointimal thickness are expressed as means ± SD. The significance of differences was determined using the ANOVA test. Statistical significance was established at a p value of <0.01.

**RESULTS**

**Generation of Retroviral Vectors**

Functional expression of the modified human iNOS cDNA in the DFGiNOS vector was tested in BOSC23 by assaying for NO2- production following transfection with DFGiNOS plasmid DNA. BOSC23 transfected with DFGiNOS produced NO2- levels of 35.3 ± 2.6 μM/48 hr versus 0.7 ± 0.2 for cells transfected with MFGlAcZ DNA (p<0.01). BOSC23 supernatants were used to infect CRIP cells to generate a stable amphotropic producer cell line. Following infection and G418 selection, a mixed CRIP-DFGiNOS cell population produced high levels of NO2- (50.9 ± 2.8 μM/24 hr) when BH4 was supplemented. In the absence of exogenous BH4, however, NO2- levels of only 4.7 ± 1.0 μM/24 hr were measured (p<0.01). BH4 is known to be an essential cofactor for all NOS enzymes, necessary in part for maintaining the active structural configuration of the enzyme (36, 37). A G418-resistant CRIP clone was found to produce DFGiNOS virus at a titer of \(5 \times 10^6\) CFU/ml and exhibited NO2- production of \(~50\text{ nmol}/10^6\text{ cells}/24\text{ hr}\) in the presence of BH4. Viral supernatant from this clone tested free of replication competent virus and was used in all subsequent experiments. Despite the reported inhibitory effect of NO on the replication of some viruses (38), no difference was detected in viral titers from BOSC23-DFGiNOS grown with or without the NOS inhibitor L-NMA (both \(~10^5\) CFU/ml). These results demonstrate that a functional iNOS retroviral vector can be generated and that certain cells may lack the BH4 synthesis required to support NO synthesis wherein BH4...
supplementation was found to be adequate to optimize iNOS activity.

Transfer and Expression of Human iNOS in Vascular Endothelial Cells

To assess endothelial cells as a potential vascular target for stable iNOS gene transfer, SPAECs were infected with the high titer DFGiNOS supernatant and selected in G418. By Northern blot analysis (Fig. 2), high levels of iNOS mRNA were found in SPAEC-DFGiNOS but not in either uninfected or BaglacZ control groups. The iNOS mRNA in SPAEC-DFGiNOS migrated at 7.5 kb, distinct from the 4.5-kb size of endogenous human hepatocyte iNOS mRNA and corresponded to the expected size for the polycistronic DFGiNOS retroviral transcript. No 4.5-kb signal was detected in any of the SPAEC groups. Stimulation of SPAEC with cytokine combinations effective in inducing iNOS expression in other cell types failed to yield detectable levels of sheep iNOS mRNA (B. R. Pitt, unpublished data). Western blot analysis of SPAEC lysates (Fig. 3) demonstrated the presence of iNOS protein in SPAEC-DFGiNOS cytosolic preparations, similar in mobility to endogenous human iNOS protein in cytosol from cytokine treated human hepatocytes (31).

NO\textsubscript{2} production (representing 40% of total nitrogen oxide metabolites) by uninfected and BaglacZ- and DFGiNOS-infected SPAEC is summarized in Fig. 4. SPAEC-DFGiNOS produced 155.0 ± 10.7 nmol/mg protein/24 hr compared with 5.5 ± 1.1 by SPAEC-BaglacZ and 6.4 ± 1.1 by uninfected cells (p < 0.01). Nitrogen oxide synthesis by these cells was inhibited by the addition of L-NMA to the culture medium. Supplemental BH\textsubscript{4} did not significantly increase NO\textsubscript{2} production, unlike the CRIP cells that had been dependent on added cofactor. The results indicate these proliferating vascular endothelial cells can express and support a functional human iNOS enzyme and that such cells could produce sufficient BH\textsubscript{4} to support NO synthesis activity.
FIG. 4. Comparison of NO\textsuperscript{2\textsuperscript{-}} production by uninfected SPAEC, SPAEC-BaglacZ, and SPAEC-DFGiNOS
Each bar represents the mean ± SD (n = 3 for each group, experiments were repeated three or more times with comparable results). l-NMA was added at 0.5 mM concentrations, while BH\textsubscript{4} was supplemented at 100 μM. *p < 0.01 versus uninfected ±L-NMA, ±BH\textsubscript{4} and BaglacZ ±L-NMA, ±BH\textsubscript{4} by ANOVA.

The expression of ecNOS is important to normal endothelial function. Therefore, the effect of sustained supraphysiologic NO synthesis by iNOS on endogenous ecNOS expression in these endothelial cells was also examined. Northern blot analysis (Fig. 5A) revealed that steady-state ecNOS mRNA levels were not significantly altered in SPAEC-DFGiNOS maintained with or without l-NMA for greater than 14 days compared with native SPAEC. Similarly, exposure of SPAEC to the exogenous NO donor SNAP (1 mM) for 6 hr resulted in a 1.5-fold increase in ecNOS mRNA versus SPAEC treated with the parent compound. Levels of ecNOS protein did not vary between protein isolated from whole cell preparations of uninfected SPAEC, SPAEC-DFGiNOS maintained in l-NMA, or SPAEC-DFGiNOS grown in the absence of l-NMA (Fig. 5B). ecNOS protein was not detectable in the cytosolic fractions from these groups (data not shown). Thus, stable expression of iNOS had minimal effects on ecNOS mRNA and protein levels.

Transfer and Expression of Human iNOS in Vascular Smooth Muscle Cells
The ability of RSMC, another vascular target cell, to support a foreign iNOS enzyme was also ex-
amined. In contrast to SPAEC, RSMC transduced with DFGiNOS produced high levels of nitrogen oxides only when BH4 was supplemented (Fig. 6A). In the presence of exogenous BH4, RSMC-DFGiNOS NO synthesis increased almost 10-fold, but in the absence of BH4 little NO2 could be measured. Northern blot analysis revealed that retroviral iNOS expression, as marked by the characteristic 7.5-kb viral iNOS transcript, was independent of BH4 availability (Fig. 6B). These data confirm that expression of human iNOS was also feasible in vascular smooth muscle cells; however, functional enzymatic activity was dependent on exogenous BH4.

Transfer and Expression of Human iNOS to Injured Porcine Femoral Arteries in Vitro
The ability to perform iNOS gene transfer to arterial vessels was evaluated in vitro with intact porcine femoral arteries in organ culture. Following balloon catheter-induced vascular injury and viral infection 5 days after injury, arterial segments infected with DFGiNOS released 3- to 4-fold more NO2- + NO3- versus uninjured vessels or MFGlacZ-infected segments (Table 1) as measured on culture Day 14. More dramatically, cGMP release by DFGiNOS infected arteries increased by 15-fold over that measured in either uninjured or injured control vessel segments. BH4 was provided to the organ cultures on a daily basis because initial results indicated nitrogen oxide and cGMP release was dependent on cofactor supplementation (data not shown). Inclusion of L-NMA in the culture media inhibited both NO2- + NO3- and cGMP release.

Staining for β-galactosidase or iNOS (Fig. 7A, top or bottom panels, respectively) in the infected arterial segments showed an estimated infection efficiency of 0.5–1%. The majority of cells expressing either enzyme were found to be located in the superficial neointimal region. While the viral infection efficiency appeared extremely low, earlier attempts to infect similar arterial segments not subjected to prior injury resulted in no detectable transgene expression. Because of this low efficiency, transgene expression was further confirmed by reverse transcriptase PCR amplification for human iNOS message. The predicted 316-bp iNOS PCR product was strongly detected only in DFGiNOS-infected vessel segments (Fig. 7B). A very low level of iNOS mRNA was detected in MFGlacZ-infected vessels. While the iNOS PCR primers did not amplify rodent iNOS sequences (data not shown), there may be some cross-reactivity with porcine iNOS sequences. Detectable iNOS expression by PCR amplification in control vessels may reflect a low level induction secondary to balloon catheter injury (39).
TABLE 1. Total nitrogen oxide and cGMP production by porcine arterial segments

<table>
<thead>
<tr>
<th>Treatment Groups</th>
<th>Total NO\textsubscript{2} and NO\textsubscript{3} (pmol/mg/24 hr)</th>
<th>(p) Value(^a) (ANOVA)</th>
<th>cGMP (fmol/mg/24 hr)</th>
<th>(p) Value(^b) (ANOVA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>29.7 ± 6.5(^b)</td>
<td>—</td>
<td>5.2 ± 2.8</td>
<td>—</td>
</tr>
<tr>
<td>Injury alone</td>
<td>35.4 ± 8.4</td>
<td>NS(^c)</td>
<td>7.3 ± 3.4</td>
<td>NS</td>
</tr>
<tr>
<td>Injury + MFGlacZ</td>
<td>40.1 ± 5.2</td>
<td>NS</td>
<td>6.8 ± 2.9</td>
<td>NS</td>
</tr>
<tr>
<td>Injury + DFGiNOS</td>
<td>121.9 ± 43.1</td>
<td>0.001</td>
<td>101.3 ± 12.1</td>
<td>0.002</td>
</tr>
<tr>
<td>Injury + DFGiNOS + l-NMA</td>
<td>37.4 ± 8.2</td>
<td>NS</td>
<td>5.6 ± 4.2</td>
<td>NS</td>
</tr>
</tbody>
</table>

\(^a\)Versus uninjured control arterial segments.
\(^b\)Values are means ± SD, \(n = 4\), representative of three separate experiments.
\(^c\)NS, not significant.

However, amplification for Neo sequences (Fig. 7B), unique to the DFGiNOS retrovirus, revealed expression solely in the DFGiNOS-infected vessels and provides additional confirmation of expression of the transferred genes.

**Effect of Human iNOS Gene Transfer on Myointima Formation**

The effect of iNOS gene transfer on myointimal proliferation in response to injury was evaluated and is summarized in Fig. 8A. Balloon catheter injury resulted in a significant increase in myointimal thickness, as determined by rhodamine phalloidin staining (Fig. 8B), in both injury alone or injury followed by infection with MFGlacZ (myointimal thicknesses of 153 and 147% of uninjured controls, respectively). In contrast, the proliferative response to balloon injury in arteries subsequently infected with DFGiNOS was markedly attenuated and essentially indistinguishable from uninjured vessels. The inhibitory effect of DFGiNOS infection on myointimal thickening was completely abrogated by l-NMA administration, indicating the effect was dependent on NO synthesis. These results show successful reduction in myointimal hypertrophy following balloon catheter-induced arterial injury with human iNOS gene transfer despite low gene transfer efficiency.

**DISCUSSION**

This study represents our initial investigation into the feasibility and biologic effectiveness of vascular human iNOS gene transfer. We constructed a retroviral vector carrying a functional human iNOS cDNA that was used to genetically modify vascular endothelial cells and smooth muscle cells to stably express iNOS. The DFGiNOS-transduced endothelial cells produced 30-fold more NO than native cells in an autonomous fashion. In contrast, smooth muscle cells required exogenous BH\(_4\) to support NO synthesis. BH\(_4\) is an essential cofactor for all NO isoforms. We have shown that NIH3T3 cells engineered to stably express human iNOS express both mRNA and protein in the absence of exogenous BH\(_4\) but only exhibits iNOS activity when BH\(_4\) is added to the cells (37). BH\(_4\) addition is associated with a conversion of intracellular iNOS protein from inactive monomers to active dimers (37). De novo BH\(_4\) synthesis is controlled by the rate-limiting enzyme GTP cyclohydrolase I (21). Select cells possess basal levels of BH\(_4\) synthesis to support enzymes such as phenylalanine hydroxylase (40) while other cells, including fibroblasts (21,37) and vascular smooth muscle cells (41), are known to lack constitutive GTP cyclohydrolase I expression and activity. In some cells, co-induction of GTP cyclohydrolase I along with iNOS occurs in response to cytokine stimulation. This co-induction serves as a mechanism to ensure sufficient BH\(_4\) to support the induced NOS activity (21,41). BH\(_4\) is present in endothelial cells to support ecNOS function and, therefore, most likely permits these cells to support a transferred iNOS enzyme without additional BH\(_4\); resting smooth muscle cells lack BH\(_4\) synthesis and, in the absence of cytokine stimulation, would be expected to be dependent on exogenous BH\(_4\) to activate the foreign iNOS protein. Thus, stable transfer of the human iNOS.
gene to naive vascular target cells utilizing a retroviral vector can be achieved, but iNOS activity is intimately linked to cofactor availability in the targeted cells.

The biologic effect of human iNOS gene transfer on myointimal thickening was assessed in an ex vivo organ culture system. Balloon catheter–induced arterial injury elicits a characteristic tissue response consisting of smooth muscle migration, proliferation, and augmented extracellular matrix deposition. These events culminate in neointima formation and myointimal thickening. An in vitro model of vascular injury using rabbit aorta with subsequent gene transfer has been established (35) and has been shown to be useful in studying the effect of various gene products on intimal hyperplasia. We adapted this model to balloon catheter–injured porcine femoral arteries where a similar injury response was reproducibly created. Human iNOS gene transfer to these injured vessel segments was accomplished with retroviral infection 5 days post-injury, a time period associated with near-maximal smooth muscle cell proliferation (35). Because of the absolute requirement for cellular replication for successful retroviral integration, infection of uninjured vessels or vessels immediately following injury resulted in poor infection efficiencies. By delaying infection until maximal cellular proliferation was achieved, our infection efficiency was improved to 1%. While this still represents a small number of cells expressing the transgene, NO synthesis and cGMP production were nonetheless significantly elevated. Despite the low efficiency of gene transfer, the level of iNOS expression and NO synthesis was sufficient to eliminate the myointimal hyperplasia associated with the vascular injury response. It is not surprising that sufficient levels of NO were synthesized by the few infected cells to dramatically influence cGMP and myointimal proliferation in vitro. NO is highly diffusable in solution and creates a “field effect” around secreting cells (42). In the absence of hemoglobin, NO would be expected to have profound effects on neighboring cells. Whether such an extensive field effect will be available in vivo remains to be determined.

The mechanism by which NO impacts on myointimal thickening and which aspects of smooth muscle migration, proliferation, and extracellular matrix deposition that iNOS gene transfer influences remains to be elucidated. While higher levels of NO release significantly reduced [3H]-thymidine incorporation (9), our early observations indicate that the levels of NO generated by the DFGiNOS-infected arterial segments have minimal effects on smooth muscle proliferation.
cell proliferation in cell culture (E. Tzeng, unpublished data). Alternatively, NO may be interfering with the synthesis of extracellular matrix components such as collagen and elastin. Strauss et al. (43) reported that cellular proliferation in myointimal lesions in a rabbit model of restenosis was modest and peaked in the first week while extracellular matrix deposition remained significantly elevated and continued to contribute to the thickening process for up to 4 weeks. Thus, in our model of arterial injury, iNOS gene transfer and NO synthesis may be acting through the inhibition of extracellular matrix synthesis by the smooth muscle cells. Indeed, we have demonstrated that cells stimulated to express iNOS or exposed to NO exhibit a marked reduction in protein synthesis (34,44).

Based on our in vitro observations, the requirement for BH$_4$ for increased NO synthesis in this arterial injury and gene transfer model suggests that iNOS gene transfer primarily targeted the vascular smooth muscle cells. This was confirmed by immunohistochemistry showing both lacZ and iNOS expression localized to the myointima. If a similar distribution of expression were to occur in vivo, a means to simultaneously increase BH$_4$ availability would be required. Possibilities include administration of exogenous BH$_4$ or BH$_4$ substrates (e.g., sepiapterin) or co-transfer of the gene for GTP cyclohydrolase I, the rate-limiting enzyme for BH$_4$ biosynthesis. Recent observations suggest that reduced NO availability may contribute to the progression of atherosclerotic disease and to the complications of therapeutic vascular intervention (15,16) as a result of the loss of the antithrombogenic and antiproliferative influences of NO. Previous data from others (17,18) and our current data suggest that restoring NO levels in diseased vasculature may have therapeutic efficacy. Interestingly, endothelial injury induces the expression of an endogenous iNOS in rat vascular smooth muscle cells (39), increasing NO production at the site of injury. Smooth muscle iNOS expression in this setting may represent an adaptive mechanism derived to prevent acute thrombosis and intimal hyperplasia at sites of injury until endothelial integrity is reestablished. This iNOS expression, however, is transient, persisting for a 1- to 2-week period, while the healing process
continues for many weeks, and may explain the failure of this endogenous iNOS expression to limit intimal lesion formation. Prevention of intimal hyperplasia with iNOS gene transfer may require that gene expression persist for several weeks if not longer. Current methods of gene delivery only offer a single option that permits long-term transgene expression, that of retroviral-mediated gene transfer. The low efficiency of retroviral gene transfer limits its utility, but our data suggest the potential for therapeutic success despite low levels of iNOS expression.

Support for both the importance of NO for restoring normal structure and function of the blood vessel wall and for the therapeutic use of NOS gene transfer to reduce restenosis comes from von der Leyen et al. (19). These authors show inhibition of intimal hyperplasia and restoration of vasoreactivity in a rat carotid artery injury model using liposome-mediated transfer of the bovine endothelial cNOS. In clinical practice, high efficiency vascular gene transfer may be difficult due to the dangers of prolonged vascular occlusion required by most gene transfer techniques. Our studies suggest that iNOS may have some advantages over cNOS. Because iNOS activity is not dependent on increases in intracellular calcium levels for activation, the activity of the expressed enzyme will be dependent only on cofactor and substrate availability, as shown by our studies in cells and tissue, and not agonists to increase intracellular free calcium. Furthermore, because the activity of iNOS is much greater than cNOS, the transfer efficiency required for production of therapeutic levels of NO may be much lower than for cNOS. With continued, rapid advances in vector and delivery system development for vascular gene therapy, specific approaches for adequate and safe transfer of NOS to blood vessels may soon be a reality.

ACKNOWLEDGMENTS

We would like to acknowledge the excellent technical assistance of Ms. Lori McKenzie, Ms. Solthi Tran, and Mr. Paul Moyer, as well as Dr. Laurence Zitvogel for helpful discussion. This work was supported in part by National Institutes of Health Grants GM-44100 (TRB), GM-37753 (RLS), DK-44935 (PDR), HL-32154 (BRP), and F32-GM-16645 (ET). TRB is the recipient of the George H. A. Clowes Jr., M.D., Memorial Research Career Development Award of the American College of Surgeons.

REFERENCES


34. Billiar TR, Curran RD, Stuehr DJ, West MA, Bentz BG, Simmons RL. (1989) An L-argi-


Contributed by E. Beutler on December 18, 1995.